Comprehensive regulatory and developmental landscape of cell-scaffold combination therapies for osteoarthritis.

Authors

Yunbin Choi, Seungyong Lee, Soobin Moon, Chaeeun Shin, Min Park, Mai Zakarya, Jihong Lim, Kyenghee Kwon

Published in

Regenerative therapy. Volume 33. Pages 101177. Epub Sep 28, 2026.

Abstract

Osteoarthritis (OA) is a common degenerative joint disease with rising prevalence in aging population. Regen-erative approaches such as autologous chondrocyte implantation (ACI) and stem cell-based therapies show promise but face limitations due to reduced cell viability and poor long-term stability. Recently, combining stem cells with biodegradable scaffolds has emerged as a promising strategy to improve cell survival and tissue regeneration.
This study compares representative approved OA-related cell-based products (CARTISTEM [UCB-MSC], JACC [ACI-Scaffold], and MACI [ACI-Scaffold]) to elucidate their developmental characteristics and regulatory pathways. It also reviews nonclinical and clinical evaluation criteria, current regulatory guidelines, and the global clinical development pipeline, to provide scientific and regulatory insights that support the advancement of future OA-related cell-scaffold combination therapies.
The comparative analysis identified differences in cellular origin, scaffold use, regulatory classification, and evidence requirements across products. These differences were associated with distinct regulatory expectations and development strategies, particularly for scaffold-containing products requiring biomaterial-related safety evaluation. The study also derived key development considerations relevant to future OA-related cell-scaffold combination therapies.
Cell-scaffold combination products require product-specific regulatory approaches and multidisciplinary evaluation. Early regulatory engagement and greater international harmonization may improve development efficiency, regulatory predictability, and the advancement of future OA-related regenerative therapies.

PMID:
42859758
Bibliographic data and abstract were imported from PubMed on 11 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.